Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Xilio Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 35 | 35 | 0 |
| Shares | 22.5M | 23.8M | +1.27M (+5.6%) |
| Value | $16.3M | $16.2M | −$139.5K (−0.9%) |
New holders (5)
Institutions that held Xilio Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ghisallo Capital Management LLC | 1,333,000 | $906.3K | 0.02% |
| Squarepoint Ops LLC | 235,456 | $160.1K | 0.00% |
| XTX Topco Ltd | 34,721 | $23.6K | 0.00% |
| LPL Financial LLC | 31,000 | $21.1K | 0.00% |
| Tower Research Capital LLC (TRC) | 15,412 | $10.5K | 0.00% |
Sold out (5)
Institutions that held Xilio Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Millennium Management LLC | 51,110 | $37.0K |
| Scientech Research LLC | 42,546 | $30.8K |
| ADAR1 Capital Management, LLC | 40,000 | $29.0K |
| Steward Partners Investment Advisory, LLC | 20,000 | $14.5K |
| JPMorgan Chase & Co | 62 | $45 |